Macropore Inc. IR-Pages
MacroPore Biosurgery Receives CE Mark Approval for Hydrosorb(TM) Boomerang(R)
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MacroPore Biosurgery Receives CE Mark Approval for Hydrosorb(TM) Boomerang(R)
MacroPore Biosurgery Receives CE Mark Approval for Hydrosorb(TM) Boomerang(R),
the First Minimally Invasive Resorbable Lumbar Interbody Fusion Device in Europe
San Diego, CA, July 1, 2004 – MacroPore Biosurgery, Inc. (Frankfurt: XMP)
(Reuters: MACP.DE) (Bloomberg: XMP) today announced that it has received the CE
Mark approval to market Hydrosorb(TM) Boomerang(R) for interbody fusion in
Europe.
end of ad-hoc-announcement (c)DGAP 01.07.2004
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
HYDROSORB (TM) Boomerang(R) implants will be marketed in Europe for spinal
fusion procedures when vertebral discs are damaged after trauma, disease or age-
related degeneration. They are made from a polylactide (PLa) resorbable material
that provides temporary support while healing takes place. The material then
naturally resorbs into the body over time. The products will be manufactured by
MacroPore Biosurgery and distributed throughout Europe by Medtronic Sofamor
Danek.
“This is an important extension to our Hydrosorb(TM) line as it represents the
very first resorbable, minimally invasive lumbar interbody fusion device in
Europe,” said Sharon Schulzki, Chief Operating Officer, MacroPore Biosurgery.
“Traditional approaches to spine fusion surgery involve extensive surgical
exposure and prolonged periods of retraction that can injure back muscles and
lead to considerable post-surgical pain. To help minimize these issues, minimal
access surgical techniques have been developed. The availability of
HYDROSORB(TM) Boomerang(R) for use in minimal access insertion techniques
enables the surgeon to combine the benefits of a resorbable interbody device
with the advantages of existing minimal access technology.”
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) is focused on the discovery, development
and commercialization of regenerative medicine technologies. We have two
technology platforms, bioresorbable technology and regenerative cell technology.
Our surgical implants, derived from our bioresorbable technology, represent one
of the latest advancements in spine and orthopedic medicine. They are
manufactured by us and distributed exclusively through Medtronic Sofamor Danek.
Within our regenerative cell technology program, we are developing a system to
isolate autologous, homologous-use, regenerative cells. Simultaneously, we are
generating scientific knowledge through internal research to support the
clinical use of these cells. Our most advanced research and development program
is in the repair of cardiovascular tissues that are damaged after a heart
attack. We are also researching applications in bone repair, spinal disc
regeneration, and cosmetic and reconstructive surgery. For further information
please visit our web site http://www.macropore.com.
Contact:
MacroPore Biosurgery, Inc.
Tom Baker
Media & U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
MacroPore Biosurgery, Inc.
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
Cautionary Statement Regarding Forward-Looking Statements
This press release may include forward-looking statements regarding events and
trends which may affect MacroPore Biosurgery’s future operating results and
financial position. Such statements are subject to risks and uncertainties that
could cause MacroPore Biosurgery’s actual results and financial position to
differ materially. These risks and uncertainties are described (under the
heading “Risk Factors”) in our 2003 Form 10-K annual report for the year ended
December 31, 2003, which is available on our web site. MacroPore Biosurgery
assumes no responsibility to publicly release the results of any revision of
forward-looking statements to reflect events, trends or circumstances after the
date they are made.
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
010800 Jul 04
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden